Patisiran Infusion 0.3 mg/mL Suppliers & Bulk Manufacturers
Available Forms: Intravenous (IV) infusion
Available Strengths: 0.3 mg/mL
Reference Brands: Onpattro
Category: Nanoemulsion/Nanoparticles
Patisiran (Onpattro) inhibits transthyretin (TTR) production in the liver via RNA interference, reducing misfolded TTR protein accumulation. Benefits include slowing disease progression, alleviating neurological and cardiac symptoms, and improving quality of life in hereditary transthyretin amyloidosis patients when administered properly in specialized centers.
Product Description:
Patisiran (Onpattro) is regulated in both the EU and US, supported by dossiers demonstrating safety, efficacy, and manufacturing quality in compliance with GMP standards. In the US, FDA approval involved rigorous clinical validation, safety assessments, and pharmacovigilance. In the EU, CE marking certifies conformity under MDR standards. These biologics undergo validation, stability testing, and audits, with comprehensive documentation including safety profiles, clinical trial data, and manufacturing practices. For licensing procedures, approved dossiers, and the latest regulatory updates, visit Pharmatradz. Ensuring compliance guarantees access to effective, life-saving therapies supporting patients with hereditary ATTR amyloidosis worldwide, promoting safe and optimal patient outcomes.
Patisiran Infusion — third party manufacturing & bulk supply
Patisiran Infusion 0.3 mg/mL is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Indicative minimum order quantity
Patisiran Infusion is supplied as Intravenous (IV) infusion — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.
Manufacturers of Patisiran Infusion listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Patisiran Infusion →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Related Products
Covid-19 Vaccine
Strength:
30 µg per dose
Form: Vial for reconstitution (injectable, intramuscular)
Reference Brands: Comirnaty
View Details
Givosiran Infusion
Strength:
2.5 mg/kg IV infusion
Form: Intravenous infusion
Reference Brands: Givlaari
View DetailsQuick Response Guaranteed | Verified Suppliers
